Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:50 UTC
Update Date2022-03-07 02:51:44 UTC
HMDB IDHMDB0014754
Secondary Accession Numbers
  • HMDB14754
Metabolite Identification
Common NameCandoxatril
DescriptionCandoxatril is only found in individuals that have used or taken this drug. It is the orally-active prodrug of candoxatrilat (UK-73967), the active enantiomer of candoxatrilat (UK-69578), a potent neutral endopeptidase (NEP) inhibitor used in the treatment of chronic heart failure.Neutral endopeptidase inhibitors such as Candoxatril have a dual mechanism of action. They inhibit two metalloprotease enzymes, neutral endopeptidase and ACE, resulting in an increased availability of natriuretic peptides that exhibit vasodilatory effects and, possibly, tissue protective effects.
Structure
Data?1582753217
Synonyms
ValueSource
4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acidChEBI
[4(S)-cis]-4-[[[1-[3-[(2,3-Dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acidChEBI
4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylateGenerator
[4(S)-cis]-4-[[[1-[3-[(2,3-Dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylateGenerator
Chemical FormulaC29H41NO7
Average Molecular Weight515.6383
Monoisotopic Molecular Weight515.288302671
IUPAC Name(1s,4s)-4-{1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentaneamido}cyclohexane-1-carboxylic acid
Traditional Namecandoxatril
CAS Registry Number118785-03-8
SMILES
COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1
InChI Identifier
InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21-,23-,24+/m0/s1
InChI KeyZTWZVMIYIIVABD-OEMFJLHTSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as indanes. Indanes are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassIndanes
Sub ClassNot Available
Direct ParentIndanes
Alternative Parents
Substituents
  • Indane
  • Fatty acid ester
  • Dicarboxylic acid or derivatives
  • Fatty amide
  • Fatty acyl
  • Carboxamide group
  • Secondary carboxylic acid amide
  • Carboxylic acid ester
  • Ether
  • Dialkyl ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organic oxygen compound
  • Carbonyl group
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.0022 g/LNot Available
LogP3.7Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.0022 g/LALOGPS
logP3.55ALOGPS
logP4.68ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.29ChemAxon
pKa (Strongest Basic)1.32ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.16 ŲChemAxon
Rotatable Bond Count13ChemAxon
Refractivity138.16 m³·mol⁻¹ChemAxon
Polarizability57.2 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+219.2931661259
DarkChem[M-H]-220.79831661259
DeepCCS[M+H]+221.98330932474
DeepCCS[M-H]-219.58830932474
DeepCCS[M-2H]-252.74530932474
DeepCCS[M+Na]+227.94630932474
AllCCS[M+H]+219.832859911
AllCCS[M+H-H2O]+218.632859911
AllCCS[M+NH4]+220.932859911
AllCCS[M+Na]+221.332859911
AllCCS[M-H]-203.432859911
AllCCS[M+Na-2H]-205.332859911
AllCCS[M+HCOO]-207.632859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
CandoxatrilCOCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C14811.4Standard polar33892256
CandoxatrilCOCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C13973.4Standard non polar33892256
CandoxatrilCOCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C13922.8Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Candoxatril,1TMS,isomer #1COCCOC[C@H](CC1(C(=O)N[C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)CCCC1)C(=O)OC1=CC=C2CCCC2=C13935.2Semi standard non polar33892256
Candoxatril,1TMS,isomer #2COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C14063.8Semi standard non polar33892256
Candoxatril,2TMS,isomer #1COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C13960.0Semi standard non polar33892256
Candoxatril,2TMS,isomer #1COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C13752.0Standard non polar33892256
Candoxatril,2TMS,isomer #1COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C14730.7Standard polar33892256
Candoxatril,1TBDMS,isomer #1COCCOC[C@H](CC1(C(=O)N[C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)CCCC1)C(=O)OC1=CC=C2CCCC2=C14177.0Semi standard non polar33892256
Candoxatril,1TBDMS,isomer #2COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C14288.4Semi standard non polar33892256
Candoxatril,2TBDMS,isomer #1COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C14408.7Semi standard non polar33892256
Candoxatril,2TBDMS,isomer #1COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C14132.6Standard non polar33892256
Candoxatril,2TBDMS,isomer #1COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C14847.2Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Candoxatril GC-MS (Non-derivatized) - 70eV, Positivesplash10-001i-8903400000-268da98bf001b2697ad32017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Candoxatril GC-MS (1 TMS) - 70eV, Positivesplash10-00ea-9701230000-415d420bb3afba46e0382017-10-06Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Candoxatril 90V, Positive-QTOFsplash10-00pl-9200000000-bc11c66d3ece45e09e882021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Candoxatril 75V, Positive-QTOFsplash10-00pi-9600000000-83441da8ede7797f50e72021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Candoxatril 45V, Positive-QTOFsplash10-057r-2900000000-60fd63861087a3fe92d92021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Candoxatril 60V, Positive-QTOFsplash10-057i-6900000000-d1197406ad3d8cefddfa2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Candoxatril 45V, Positive-QTOFsplash10-057r-2900000000-0e86e71ecc29989958e82021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Candoxatril 15V, Positive-QTOFsplash10-053r-0009000000-f592f37f904e3e76bf192021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Candoxatril 30V, Positive-QTOFsplash10-0569-1986000000-e7ba3bddb330c80b7ce92021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 10V, Positive-QTOFsplash10-014i-0714950000-0d88710626c10ccc68952016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 20V, Positive-QTOFsplash10-014i-1924400000-1212988199020b7a6e782016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 40V, Positive-QTOFsplash10-015c-4951100000-c7b3c19e54fc433cebc62016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 10V, Negative-QTOFsplash10-03di-2302690000-82a62f70e9d322ce04e42016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 20V, Negative-QTOFsplash10-0h60-1409510000-c92b3392f22113ddb47a2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 40V, Negative-QTOFsplash10-001i-6910000000-a9c7701cff60595f64542016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 10V, Positive-QTOFsplash10-014i-0001390000-c54e9b5c348fb07577102021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 20V, Positive-QTOFsplash10-017i-3386960000-eb7472fe7ae2532061292021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 40V, Positive-QTOFsplash10-0170-6921420000-e5f0c1c9c0d663cf9dff2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 10V, Negative-QTOFsplash10-0bt9-0010910000-64ff1f2df639c0ba09b22021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 20V, Negative-QTOFsplash10-000f-0736910000-09ca3f3a4172911e6edc2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Candoxatril 40V, Negative-QTOFsplash10-01ox-8912370000-d08f092f5a2aef1c655f2021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Extracellular
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00616 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00616 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00616
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID16736409
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkCandoxatril
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI ID3353
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General ReferencesNot Available

Enzymes

General function:
Involved in metallopeptidase activity
Specific function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety
Gene Name:
ACE
Uniprot ID:
P12821
Molecular weight:
149713.7
References
  1. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D: Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001 Apr;37(4):359-66. [PubMed:11300648 ]
  2. Kostova E, Jovanoska E, Zafirov D, Jakovski K, Maleska V, Slaninka-Miceska M: Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats. Bratisl Lek Listy. 2005;106(12):407-11. [PubMed:16642666 ]
General function:
Involved in metalloendopeptidase activity
Specific function:
Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids. Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond. Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9. Involved in the degradation of atrial natriuretic factor (ANF)
Gene Name:
MME
Uniprot ID:
P08473
Molecular weight:
85513.2
References
  1. O'Connell JE, Jardine AG, Davidson G, Connell JM: Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. [PubMed:1315825 ]
  2. Elsner D, Muntze A, Kromer EP, Riegger GA: Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 1992 Aug 15;70(4):494-8. [PubMed:1386491 ]
  3. Plamboeck A, Holst JJ, Carr RD, Deacon CF: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005 Sep;48(9):1882-90. Epub 2005 Jul 16. [PubMed:16025254 ]
  4. Sansoe G, Aragno M, Mastrocola R, Cutrin JC, Silvano S, Mengozzi G, Smedile A, Rosina F, Danni O, Rizzetto M: Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis. Am J Physiol Renal Physiol. 2006 Jun;290(6):F1337-43. Epub 2006 Jan 31. [PubMed:16449355 ]
  5. Hirata Y, Suzuki E, Hayakawa H, Matsuoka H, Sugimoto T, Kangawa K, Matsuo H: Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol. 1994 Feb;23(2):283-90. [PubMed:7511759 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]